Back to Browse Journals » International Journal of Women's Health » Volume 1

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

Authors SA Kingsberg, S Kellogg, M Krychman

Published 20 August 2009 Volume 2009:1 Pages 105—111


Review by Single-blind

Peer reviewer comments 2

SA Kingsberg¹, S Kellogg², M Krychman³

1University Hospitals Case Medical Center, Case Western Reserve University Cleveland OH, USA; 2The Pelvic and Sexual Health Institute of Philadelphia, Drexel University College of Medicine, Philadelphia, USA; 3Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, CA, USA

Abstract: Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia resulting from vulvovaginal atrophy will depend on the underlying etiology and might include individualized treatment. A number of forms of vaginal estrogen and manner of delivery are currently available to treat moderate to severe dyspareunia caused by VVA. They all have been shown to be effective and are often the preferred treatment due to the targeted efficacy for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare professionals and patients often find it difficult to broach the subject of sexual problems associated with VVA. However, with minimal effort to initiate a conversation about these problems, healthcare providers can provide useful information to their postmenopausal patients in order to help them each choose the optimal treatment for their needs and symptoms.

Keywords: dyspareunia, postmenopausal vulvovaginal atrophy, vaginal estrogen therapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey

Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS, Kim SK, Chang J, Chung KS

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1571-1582

Published Date: 7 August 2015

Fabrication of nanoadjuvant with poly-ɛ-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity [Corrigendum]

Prashant CK, Bhat M, Srivastava SK, Saxena A, Kumar M, Singh A, Samim M, Ahmad FJ, Dinda AK

International Journal of Nanomedicine 2014, 9:4033-4034

Published Date: 21 August 2014

Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia [Corrigendum]

Kinoshita Y, DiBonaventura M, Rossi B, Iwamoto K, Wang ECY, Briere JB

Clinical and Experimental Gastroenterology 2013, 6:193-194

Published Date: 23 September 2013

Erratum - Intracellular heavy metal nanoparticle storage

Iannitti T, Capone S, Gatti A, et al

International Journal of Nanomedicine 2011, 6:239-240

Published Date: 26 January 2011

Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy

Tommaso Iannitti, Stefania Capone, Antonietta Gatti, et al

International Journal of Nanomedicine 2010, 5:955-960

Published Date: 15 November 2010

Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice

Jun Wang, Yue Chen, Baoan Chen, et al

International Journal of Nanomedicine 2010, 5:861-866

Published Date: 13 October 2010

Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells

Xinying Wu, Yanbin Tan, Hui Mao, et al

International Journal of Nanomedicine 2010, 5:385-399

Published Date: 26 May 2010

Tinidazole in the treatment of bacterial vaginosis

Nicola R Armstrong, Janet D Wilson

International Journal of Women's Health 2009, 1:59-65

Published Date: 25 June 2009

Progress in analgesia for labor: focus on neuraxial blocks

J Sudharma Ranasinghe, David J Birnbach

International Journal of Women's Health 2009, 1:31-43

Published Date: 18 May 2009